E. coli Asparaginase — Competitive Intelligence Brief

E. coli Asparaginase (E. coli Asparaginase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme. Area: Oncology.

phase 3 Enzyme Asparagine Oncology Small molecule

Target snapshot

E. coli Asparaginase (E. coli Asparaginase) — Dana-Farber Cancer Institute. E. coli asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
E. coli Asparaginase TARGET	E. coli Asparaginase	Dana-Farber Cancer Institute	phase 3	Enzyme	Asparagine
Asparlas	calaspargase	Pfizer	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2018-01-01
ASPARAGINASE ERWINIA CHRYSANTHEMI	ASPARAGINASE ERWINIA CHRYSANTHEMI		marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2011-01-01
Elspar	ASPARAGINASE	Merck & Co.	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	1994-01-01
Erwinia asparaginase	Erwinia asparaginase	Andrew E. Place, MD	marketed	Enzyme	Asparagine
recombinant asparaginase	recombinant asparaginase	medac GmbH	marketed	Enzyme	Asparagine
L-asparaginase	L-asparaginase	ERYtech Pharma	marketed	Enzyme (asparagine depleting agent)	Asparagine (substrate depletion mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme class)

1. Andrew E. Place, MD · 1 drug in this class
2. Dana-Farber Cancer Institute · 1 drug in this class
3. Medsearch · 1 drug in this class
4. medac GmbH · 1 drug in this class